ArticleBMC infectious diseases2025
Serum asprosin levels as a potential prognostic biomarker in COVID-19: insights for future respiratory viral pandemics.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the initial surge of the COVID-19 pandemic has passed, identifying prognostic biomarkers remains critical for managing severe cases and preparing for future respiratory viral outbreaks. Asprosin, a metabolic hormone involved in energy homeostasis and inflammation, has been linked to cardiometabolic disorders, but its relationship with COVID-19 severity has not been fully elucidated. This prospective study aimed to investigate the association between serum asprosin levels, disease severity, and clinical outcomes in COVID-19 patients.
methodsA total of 121 participants were enrolled, including 95 hospitalized patients with RT-PCR-confirmed COVID-19 and 26 PCR-negative controls. Patients were classified into mild, moderate, or severe pneumonia groups based on chest CT findings. Demographic, clinical, and laboratory parameters-including serum asprosin-were analyzed for differences between groups and correlations with disease severity.
resultsSerum asprosin levels were significantly higher in COVID-19 patients compared to controls (p < 0.001) and served as an independent predictor of COVID-19 positivity (OR = 2.13, p = 0.017). ROC analysis demonstrated strong diagnostic performance (AUC = 0.849, p < 0.001), with a cut-off of 4.71 ng/mL yielding 98.9% sensitivity and 69.2% specificity. COVID-19 patients also showed higher ferritin, CRP, and urea, and lower platelet and albumin levels (p < 0.001). Mortality was strongly associated with pneumonia severity (p < 0.001); low oxygen saturation and hypertension emerged as independent predictors of severity. Asprosin correlated positively with fibrinogen and negatively with comorbidity count. Patients with diabetes mellitus had significantly lower asprosin levels (p = 0.042), while no significant differences were observed according to mortality status.
conclusionsElevated serum asprosin in COVID-19 patients suggests involvement in metabolic and inflammatory responses. Although unrelated to disease severity, it may aid diagnosis and reflect systemic stress. Larger multicenter studies are needed to confirm its biomarker and therapeutic potential. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.